The mitochondrial messenger for metabolic vitality
A 16-residue mitochondrial-derived peptide involved in metabolic and exercise signaling.
Educational content. This page describes MOTS-c for informational purposes only and is not medical advice, diagnosis, or treatment. Consult a licensed provider before starting, stopping, or modifying any therapy.
Reduces myostatin expression and downstream atrophy signaling, helping preserve lean mass during aging or caloric restriction.[5]
MOTS-c (Mitochondrial Open reading frame of the Twelve S rRNA type-c) is a 16-amino-acid peptide encoded within the mitochondrial genome. Discovered in 2015 by Dr. Changhan Lee at USC, it was the first mitochondrial-derived peptide shown to regulate metabolism in distant tissues.
MOTS-c is naturally produced, with levels that fluctuate in response to exercise, diet, and aging. Circulating MOTS-c increases after exercise and declines with age, suggesting it may mediate exercise's metabolic benefits.
MOTS-c primarily activates AMP-activated protein kinase (AMPK), the body's master metabolic switch, promoting glucose uptake in skeletal muscle, enhancing fatty acid oxidation, and shifting metabolism toward efficient energy production.
Uniquely, MOTS-c can translocate from the cytoplasm to the nucleus during metabolic stress, directly modulating gene expression through antioxidant response elements (AREs).
It also reduces myostatin expression and attenuates muscle atrophy signaling, helping preserve lean mass during aging or caloric restriction.
The mitochondrial messenger for metabolic vitality
MOTS-c is a mitochondrial-encoded peptide that activates AMPK to enhance glucose uptake and fatty acid oxidation. During metabolic stress, it translocates to the nucleus to regulate gene expression through AREs, while reducing myostatin-mediated muscle atrophy and improving mitochondrial function.
Key studies supporting the therapeutic use of this peptide.
Prevented diet-induced obesity and insulin resistance, improving glucose tolerance.
Lee C, Zeng J, Drew BG, et al. — Cell Metab, 21(3):443-454 (2015) · PubMed
MOTS-c levels rise with exercise, decline with age. Treatment improved physical capacity and muscle homeostasis in aged mice.
Reynolds JC, Lai RW, Woodhead JST, et al. — Nat Commun, 12(1):470 (2021) · PubMed
Significantly reduced myostatin and downstream atrophy markers (MuRF1, Atrogin-1).
Kumagai H, Coelho AR, Wan J, et al. — Am J Physiol Endocrinol Metab, 320(4):E680-E690 (2021) · PubMed
Typical protocols used in clinical practice. Always consult a licensed provider for personalized dosing.
Subcutaneous Injection
Subcutaneous Injection: No standardized human dose; extrapolated from animal studies
Dosing is based on translational research and clinical experience, not large-scale trials.
Practitioners typically start at 5 mg 3x/week and assess tolerance.
Some recommend timing around training sessions due to exercise-mimetic properties.
Endogenous peptide naturally produced by human mitochondria. Preclinical studies show no toxicity, hypoglycemia, or adverse hormonal effects.
No large-scale human RCTs. Current use is entirely based on preclinical research.
Theoretical concern about interactions with diabetes medications (hypoglycemia) and cancer biology (AMPK's complex role in tumor metabolism).
See how MOTS-c compares to peptides with overlapping benefits.
| Peptide | Primary Use | Administration | Cycle Length | Key Differentiator |
|---|---|---|---|---|
| MOTS-c | Metabolic Optimization & Anti-Aging | Injection (3-5x weekly) | 4–8 weeks | Only mitochondrial-derived peptide shown to act as exercise mimetic via AMPK activation and mitochondria-to-nucleus signaling |
| SS-31 (Elamipretide) | Mitochondrial Restoration & Anti-Aging | Injection (daily) | Continuous (weeks to months) | Only peptide that directly targets cardiolipin on the inner mitochondrial membrane to restore electron transport chain efficiency |
| Semaglutide | Weight Loss | Injection (weekly), Oral (daily) | Ongoing | Most clinically validated weight-loss peptide with cardiovascular outcomes data from the SELECT trial |
| Tirzepatide | Weight Loss | Injection (weekly) | Ongoing | Only dual GIP/GLP-1 agonist, producing up to 22.5% weight loss — the highest of any pharmacotherapy |
| Tesamorelin | Body Composition & GHRH | Subcutaneous Injection | Ongoing daily | The only FDA-approved GHRH analog with Phase III data in over 800 patients, proven hepatoprotective effects, and physiologic pulsatile GH release |
Current FDA classification and compounding eligibility.
The FDA placed this substance in Category 2 of the 503A bulk drug substances evaluation, flagging significant safety risks. 503A compounding carries FDA enforcement risk, so most pharmacies decline to prepare it and many physicians hesitate to prescribe it.
In April 2026, HHS Secretary Robert F. Kennedy Jr. announced that nominators withdrew 12 peptides from Category 2 of the FDA's 503A bulk drug substances evaluation, including this one. The FDA referred them to its Pharmacy Compounding Advisory Committee (PCAC) for re-evaluation at meetings beginning July 2026. If PCAC recommends Category 1 status and the FDA agrees, licensed 503A pharmacies could compound it under FDA enforcement discretion again. The outcome is not final.
Listed in Category 2 since September 2023. FDA has not identified any human exposure data for drug products containing MOTS-c via any route. Immunogenicity and impurity concerns cited. Not eligible for compounding.
Placed in 503A Category 2 with significant safety risks identified
Last verified April 12, 2026. PepHookup tracks public FDA actions. This is not legal or medical advice.
Looking into MOTS-c? Find a provider who knows this peptide and can walk you through your options.
Find a ProviderA GLP-1 receptor agonist that slows gastric emptying and reduces appetite signaling.
Approved as Ozempic and Wegovy for diabetes and chronic weight management; compounding increasingly restricted.
A dual GIP and GLP-1 receptor agonist developed for diabetes and weight management.
Approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management.
A stabilized 44-residue GHRH analog that stimulates endogenous growth hormone secretion.
FDA-approved as Egrifta for HIV-associated lipodystrophy; strongest clinical evidence of the GHRH analog family.